menu
    • menu
    [{"orgOrder":0,"company":"Berkshire Biomedical","sponsor":"National Institute of Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"Methadone","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Berkshire Biomedical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Berkshire Biomedical \/ National Institute of Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"Berkshire Biomedical \/ National Institute of Drug Abuse"}]

    Find Clinical Drug Pipeline Developments & Deals by Berkshire Biomedical

    Menu

    Berkshire Biomedical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Berkshire Biomedical

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Berkshire Biomedical

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methadone

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : National Institute of Drug Abuse

                            Deal Size : $2.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Berkshire Biomedical Awarded Phase II Funding for NIH Research Grant to Support Continued Development of the C...

                            Details : COPA is a novel oral liquid dispensing system with remote monitoring and advanced analytics, specifically designed to deliver accurate and precise doses of controlled and non-controlled prescription medications to only a biometrically Authenticated Inten...

                            Brand Name : COPA

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 07, 2022

                            Lead Product(s) : Methadone

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : National Institute of Drug Abuse

                            Deal Size : $2.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth